menu
    • menu
    [{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Targeted Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Onternabez","moa":"CNR","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tetra BioPharma \/ Targeted Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Tetra BioPharma \/ Targeted Pharmaceuticals"},{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Atropine Sulfate","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"CMC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CMC Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"CMC Pharmaceuticals \/ US Department of Defense"},{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"CMC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CMC Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"CMC Pharmaceuticals \/ US Department of Defense"},{"orgOrder":0,"company":"Corventum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CVT-130","moa":"Metabolism","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"Corventum","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corventum \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Corventum \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Corventum

                            Country arrow
                            COMPAMED
                            Not Confirmed

                            Corventum

                            Country arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CVT-130

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Corventum Announces IND Clearance for CVT-130 to Prevent Anthracycline Cardiotoxicity

                            Details : CVT-130, a miscellaneous product targeting metabolism, shows promise in treating anthracycline-related cardiotoxicity.

                            Product Name : CVT-130

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 14, 2025

                            Lead Product(s) : CVT-130

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CytoAgents

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : IND Enabling

                            Sponsor : TFS Health Science

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CytoAgents Announces FDA Acceptance of IND Application for CTO1681 to Treat Cytokine Release Syndrome in Oncol...

                            Details : CTO1681 reduces cytokines generated during CRS induced by bispecific antibodies without causing systemic off-target effects or increasing the risk of neurotoxicity like current CRS treatments.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 11, 2023

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : IND Enabling

                            Sponsor : TFS Health Science

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CMC Pharmaceuticals

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            CMC Pharmaceuticals

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine Sulfate,Scopolamine

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : IND Enabling

                            Sponsor : US Department of Defense

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CMC Pharmaceuticals Awarded Sequential Phase II SBIR Grant to Continue Pharmaceutical Development of a Medical...

                            Details : The funding will support the continued development of a promising medical countermeasure for nerve agents that contain a stable, fixed-dose combination formulation of atropine and scopolamine.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 06, 2022

                            Lead Product(s) : Atropine Sulfate,Scopolamine

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : IND Enabling

                            Sponsor : US Department of Defense

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tetra BioPharma

                            Canada arrow
                            COMPAMED
                            Not Confirmed

                            Tetra BioPharma

                            Canada arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Onternabez

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : IND Enabling

                            Sponsor : Targeted Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tetra Bio-Pharma Initiates Additional Studies on Leading Drug Candidate ARDS-003

                            Details : Tetra Bio-Pharma have initiated other research projects with Targeted Pharmaceuticals through its research agreement with the George Mason University NCBID to investigate the potential benefits of ARDS-003 in neuroinflammation and other antiviral applica...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 26, 2021

                            Lead Product(s) : Onternabez

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : IND Enabling

                            Sponsor : Targeted Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth